271 related articles for article (PubMed ID: 33296708)
21. miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway.
Wu T; Hu H; Zhang T; Jiang L; Li X; Liu S; Zheng C; Yan G; Chen W; Ning Y; Li Y; Lu Z
Oxid Med Cell Longev; 2019; 2019():9719723. PubMed ID: 31316723
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
23. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
24. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
25. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis.
Gill MK; Christova T; Zhang YY; Gregorieff A; Zhang L; Narimatsu M; Song S; Xiong S; Couzens AL; Tong J; Krieger JR; Moran MF; Zlotta AR; van der Kwast TH; Gingras AC; Sicheri F; Wrana JL; Attisano L
Nat Commun; 2018 Aug; 9(1):3510. PubMed ID: 30158528
[TBL] [Abstract][Full Text] [Related]
26. YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts.
Qin Z; Xia W; Fisher GJ; Voorhees JJ; Quan T
Cell Commun Signal; 2018 Apr; 16(1):18. PubMed ID: 29695252
[TBL] [Abstract][Full Text] [Related]
27. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
Liu F; Lagares D; Choi KM; Stopfer L; Marinković A; Vrbanac V; Probst CK; Hiemer SE; Sisson TH; Horowitz JC; Rosas IO; Fredenburgh LE; Feghali-Bostwick C; Varelas X; Tager AM; Tschumperlin DJ
Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L344-57. PubMed ID: 25502501
[TBL] [Abstract][Full Text] [Related]
28. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
29. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
30. YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription.
Fan Y; Gao Y; Rao J; Wang K; Zhang F; Zhang C
Cell Physiol Biochem; 2017; 41(3):1189-1198. PubMed ID: 28472799
[TBL] [Abstract][Full Text] [Related]
31. The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization.
Yoo G; Kim T; Chung C; Hwang DS; Lim DS
Biochem Biophys Res Commun; 2017 Aug; 490(3):650-656. PubMed ID: 28634071
[TBL] [Abstract][Full Text] [Related]
32. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
33. YAP and TAZ are essential for basal and squamous cell carcinoma initiation.
Debaugnies M; Sánchez-Danés A; Rorive S; Raphaël M; Liagre M; Parent MA; Brisebarre A; Salmon I; Blanpain C
EMBO Rep; 2018 Jul; 19(7):. PubMed ID: 29875149
[TBL] [Abstract][Full Text] [Related]
34. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.
Ando T; Charindra D; Shrestha M; Umehara H; Ogawa I; Miyauchi M; Takata T
Oncogene; 2018 Jan; 37(2):263-270. PubMed ID: 28925394
[TBL] [Abstract][Full Text] [Related]
35. TBK1 regulates YAP/TAZ and fibrogenic fibroblast activation.
Aravamudhan A; Haak AJ; Choi KM; Meridew JA; Caporarello N; Jones DL; Tan Q; Ligresti G; Tschumperlin DJ
Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L852-L863. PubMed ID: 32159970
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.
Zanconato F; Forcato M; Battilana G; Azzolin L; Quaranta E; Bodega B; Rosato A; Bicciato S; Cordenonsi M; Piccolo S
Nat Cell Biol; 2015 Sep; 17(9):1218-27. PubMed ID: 26258633
[TBL] [Abstract][Full Text] [Related]
38. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
39. Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways.
Santinon G; Pocaterra A; Dupont S
Trends Cell Biol; 2016 Apr; 26(4):289-299. PubMed ID: 26750334
[TBL] [Abstract][Full Text] [Related]
40. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
